A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from a Phase 3 clinical trial for its Lucentis biosimilar.
Read More
Novartis AMD drug Beovu secures European approval
European drug regulators have followed in the footsteps of their Australian and US counterparts, following the approval of Novartis’ new anti-VEGF therapy.
Read More
Read More
Australian CL manufacturer pens long-term deal with Chinese medical firm
Australia’s Capricornia Contact Lens is set to take its specialty products to the lucrative Chinese market after signing a 10-year distribution deal with a major pharmaceutical and medical equipment distributer.
Read More
Read More
New smart contact lens design solves hydration problem
A new smart contact lens design capable of preventing dry eye has the potential to solve a significant problem associated with the emerging technology.
Read More
Read More